Ascentage Pharma
Latest round
- Series C
Last raised
- Jul 2018
Total raised
- $237M
Investors
- 13
About Ascentage Pharma
Founded in 2009 and based in Suzhou, China, Ascentage Pharma is a biopharmaceutical company that focuses on original drug discovery and development. It has branches in Beijing, Shanghai, Guangzhou, Taizhou, the United States, and Australia.D. supervisor at Sun Yat-sen University Cancer Center. The company cooperates with UNITY Biotechnology and MD Anderson Cancer Center. Ascentage Pharma has acquired 16 ODDs(Orphan Drug Designation) from the US FDA(Food and Drug Administration). In October 2019, the company was listed on the Hong Kong Stock Exchange with stock code 6855.307 million shares in the company in a PIPE transaction. In January 2025, it was listed on the NASDAQ. The company is committed to developing innovative drugs in the fields of oncology, hepatitis B, and age-related diseases. The marketed products include Olverembatinib, which is suitable for chronic myeloid leukemia, acute lymphocytic leukemia, and gastrointestinal stromal tumors. The products under development include Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), and APG-5918. APG-2575 selectively inhibits BCL-2 protein and restores the normal apoptosis process of cancer cells, thereby achieving the goal of treating tumors. It is suitable for small lymphocytic lymphoma and multiple myeloma. The company generates revenue by providing innovative drugs in the therapeutic areas of oncology, hepatitis B, and aging-related diseases.
Who invested in Ascentage Pharma
13 investors across 3 rounds
See all investors in Ascentage Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ascentage Pharma
Who invested in Ascentage Pharma?
Ascentage Pharma has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ascentage Pharma raised?
Ascentage Pharma has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Ascentage Pharma last raise money?
Ascentage Pharma's most recent round on record is a Series C, in Jul 2018.
What does Ascentage Pharma do?
Founded in 2009 and based in Suzhou, China, Ascentage Pharma is a biopharmaceutical company that focuses on original drug discovery and development.
Where is Ascentage Pharma headquartered?
Ascentage Pharma is headquartered in Suzhou, China.
Which VCs invest in companies like Ascentage Pharma?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Ascentage Pharma's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Ascentage Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.